Personalis, Inc. (PSNL)
NASDAQ: PSNL · Real-Time Price · USD
16.57
+0.22 (1.35%)
At close: Sep 24, 2026, 4:00 PM EDT
16.51
-0.06 (-0.36%)
After-hours: Sep 24, 2026, 7:45 PM EDT
Personalis Revenue
Personalis had revenue of $22.36M in the quarter ending June 30, 2026, with 29.96% growth. This brings the company's revenue in the last twelve months to $69.67M, down -13.26% year-over-year. In the year 2025, Personalis had annual revenue of $69.65M, down -17.69%.
Revenue (ttm)
$69.67M
Revenue Growth
-13.26%
P/S Ratio
25.40
Revenue / Employee
$267,958
Employees
260
Market Cap
1.77B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 69.65M | -14.97M | -17.69% |
| Dec 31, 2024 | 84.61M | 11.13M | 15.15% |
| Dec 31, 2023 | 73.48M | 8.43M | 12.97% |
| Dec 31, 2022 | 65.05M | -20.45M | -23.92% |
| Dec 31, 2021 | 85.49M | 6.85M | 8.70% |
| Dec 31, 2020 | 78.65M | 13.44M | 20.61% |
| Dec 31, 2019 | 65.21M | 27.43M | 72.62% |
| Dec 31, 2018 | 37.77M | 28.38M | 302.15% |
| Dec 31, 2017 | 9.39M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| NeoGenomics | 766.30M |
| OPKO Health | 587.90M |
| Veracyte | 561.90M |
| CareDx | 458.09M |
| GeneDx Holdings | 454.43M |
| BillionToOne | 397.41M |
| Castle Biosciences | 357.28M |
| Fulgent Genetics | 323.93M |
PSNL News
- 1 day ago - BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL) - GlobeNewsWire
- 15 days ago - BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX) - GlobeNewsWire
- 23 days ago - Tempus AI upgraded to Overweight from Neutral at Piper Sandler - TheFly
- 4 weeks ago - Personalis downgraded to Hold from Buy at Craig-Hallum - TheFly
- 7 weeks ago - Personalis reports Q2 EPS (30c), consensus (28c) - TheFly
- 7 weeks ago - Personalis says not providing guidance or conducting earnings call - TheFly
- 7 weeks ago - Personalis Reports Second Quarter Results and Recent Highlights - Business Wire
- 7 weeks ago - Personalis Earnings release: Q2 2026 - Filings